Natixis Advisors, L.P. Atara Biotherapeutics, Inc. Transaction History

Natixis Advisors, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$8.44 - $16.89 $164,318 - $328,831	-19,469 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$14.7 - $19.89 $1,984 - $2,685	-135 Reduced 0.69%	19,469 $307,000
Q3 2021 Nov 15, 2021	BUY	$11.99 - $17.9 $2,302 - $3,436	192 Added 0.99%	19,604 $351,000
Q2 2021 Aug 12, 2021	SELL	$12.89 - $16.58 $1,611 - $2,072	-125 Reduced 0.64%	19,412 $302,000
Q1 2021 May 05, 2021	SELL	$14.0 - $20.72 $30,562 - $45,231	-2,183 Reduced 10.05%	19,537 $280,000
Q4 2020 Feb 12, 2021	BUY	$12.67 - $26.23 $275,192 - $569,715	21,720 New	21,720 $426,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.13B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.